AngioDynamics, Inc. has recently released its 10-Q report. The Latham, New York-based medical technology company designs, manufactures and sells devices used in cardiovascular disease treatment, cancer care, vascular access and other minimally invasive procedures in the United States and abroad. Its businesses are organized into Med Tech and Med Device, with products that include Auryon, AlphaVac, AngioVac, NanoKnife, ports, drainage catheters, guidewires, VenaCure EVLT and Solero microwave systems.
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
For the three months ended August 31, 2026, AngioDynamics reported net sales of $80.9 million, up 6.9% from $75.7 million a year earlier. Net loss narrowed to $7.1 million, or $0.17 per diluted share, from $10.9 million, or $0.26 per diluted share, in the prior-year quarter.
Med Tech revenue rose 13.2% to $39.9 million from $35.3 million. The company said the increase was driven by higher Auryon sales of $2.4 million, higher NanoKnife sales of $1.9 million, and a $0.4 million increase in thrombus management revenue, including a $1.2 million increase in AlphaVac sales partly offset by declines of $0.5 million in AngioVac and $0.4 million in thrombolytic sales. Med Device revenue increased 1.4% to $41.0 million from $40.5 million, led by Core product growth of $1.6 million and Microwave growth of $0.5 million, partly offset by declines of $0.7 million in other Oncology products, $0.6 million in Ports and $0.3 million in Venous products.
Gross margin improved to 59.4% from 55.3%, with gross profit increasing to $48.0 million from $41.9 million. Med Tech gross margin was 66.2%, up from 62.2%, while Med Device gross margin rose to 52.7% from 49.3%. Management attributed the companywide gross margin improvement to sales volume, price and product mix of $3.7 million, tariff-related benefits of $2.1 million, and $2.9 million of benefits from product lines shifted to third-party manufacturing and other operational costs, partly offset by $2.5 million of negative production volume impact and $0.4 million of inflation.
Research and development expense increased to $8.0 million from $6.4 million, driven mainly by the timing of projects and clinical spend, which added $1.2 million, plus $0.3 million in compensation and benefits. Selling and marketing expense rose to $30.0 million from $28.1 million, mainly because of $1.0 million higher compensation and benefits, $0.6 million more consulting, travel and other selling costs, and $0.3 million more trade show and marketing spending. General and administrative expense was $12.5 million, essentially flat with $12.6 million a year earlier.
By segment, Med Tech gross profit increased to $26.4 million from $21.9 million, and Med Device gross profit rose to $21.6 million from $19.9 million. The company ended the quarter with backlog of $2.7 million, which it said primarily affected Core and Port products. Revenue in the United States was $71.1 million, up from $66.5 million, while international sales increased to $9.8 million from $9.3 million. The market has reacted to these announcements by moving the company's shares -1.59% to a price of $14.19. For the full picture, make sure to review ANGIODYNAMICS INC's 10-Q report.
